期刊
JOURNAL OF ANTIBIOTICS
卷 74, 期 6, 页码 421-423出版社
SPRINGERNATURE
DOI: 10.1038/s41429-021-00414-5
关键词
-
资金
- Canadian Institute for Health Research
- Swiss National Fund [40AR40_180205/1]
- Swedish Research Council [2017-05973]
- Major Innovation Fund program of the Ministry of Jobs, Economy and Innovation, Government of Alberta through the AMR -One Health Consortium
- Swiss National Science Foundation (SNF) [40AR40_180205] Funding Source: Swiss National Science Foundation (SNF)
- Swedish Research Council [2017-05973] Funding Source: Swedish Research Council
The average sales of new antibiotics during their first 8 years on the market are inadequate to cover costs of supplying the products, with a striking reliance on the US market accounting for 84% of sales. Additional revenues, especially from other countries, are needed to support incentives for the development of new antibiotics, with market entry rewards potentially being of particular value.
We calculate the average sales of new antibiotics during their first 8 years on the market. The discounted net present value is only $240 m in total per antibiotic, well below costs of supplying these products. The reliance on the US for sales is striking: the US market accounts for 84% of sales during the first 8 years. These facts clarify the need for additional revenues, especially from other countries, to support incentives for the development of new antibiotics. Market entry rewards may be of particular value.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据